Form 4: DURECT Director Disposes Shares Post-Merger

DURECT Corporation's Director, Gail J. Maderis, reported the disposition of all her common stock and the cancellation of stock options following the company's merger with Bausch Health Americas, Inc.

Summary

• DURECT Corporation completed a merger with Bausch Health Americas, Inc. (Parent) through its subsidiary Purchaser, effective September 11, 2025.
• The merger involved a tender offer where DURECT stockholders received $1.75 per share in cash, net of withholding taxes, plus one non-tradeable contingent value right (CVR) per share.
• The CVR represents the contractual right to receive a pro rata portion of two milestone payments, totaling up to $350,000,000 in aggregate, contingent on achievement of specified milestones.
• Following the tender offer, DURECT became the surviving entity and a wholly owned subsidiary of Parent.
• Director Gail J. Maderis disposed of 5,500 shares of common stock held directly and 20,000 shares held indirectly through the Gail J. Maderis Revocable Trust.
• Stock options held by Gail J. Maderis with exercise prices equal to or greater than the $1.75 cash amount were canceled at the Effective Time of the Merger.
• Former holders of these canceled options are eligible to receive a cash retention bonus subject to the achievement of certain net sales milestones.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing shareholders with cash and potential future upside via CVRs. While the company is no longer independent, the transaction appears to have proceeded as planned, and the director's transactions are a standard consequence of such an event.

Positives

• The merger provides DURECT shareholders with immediate cash consideration of $1.75 per share.
• Shareholders also receive potential future upside through non-tradeable contingent value rights (CVRs) tied to milestone payments up to $350,000,000 in aggregate.
• Director Gail J. Maderis, as a holder of canceled stock options, is eligible for a cash retention bonus based on net sales milestones, providing a potential future benefit.

Negatives

• DURECT Corporation ceased to be an independent publicly traded entity, becoming a wholly owned subsidiary of Bausch Health Americas, Inc.
• Stock options with exercise prices equal to or greater than the $1.75 cash amount were canceled, meaning they did not yield immediate value from the tender offer.
• The contingent value rights are non-tradeable, limiting liquidity for the potential future milestone payments.

Future Outlook

DURECT Corporation will continue as a wholly owned subsidiary of Bausch Health Americas, Inc. Future payments to CVR holders and retention bonuses for certain option holders are contingent upon the achievement of specified milestones, including net sales targets.

Industry Context

This merger represents a consolidation within the pharmaceutical or biotechnology sector, where larger entities often acquire smaller companies to gain access to specific pipelines, technologies, or market positions. The use of contingent value rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards, particularly for assets with uncertain clinical or commercial outcomes.

Comparison to Industry Standards

• The use of CVRs in this merger aligns with common practices in the pharmaceutical and biotechnology M&A landscape, where such instruments are frequently employed to provide additional consideration to selling shareholders based on the future performance of acquired assets.
• Similar structures have been seen in acquisitions like Sanofi's acquisition of Principia Biopharma or Bristol Myers Squibb's acquisition of Celgene, where CVRs were used to provide contingent payments tied to regulatory approvals or sales milestones of specific drug candidates.
• The $1.75 cash per share, combined with potential CVRs up to $350 million, reflects a valuation approach common for companies with development-stage assets or specific market niches.

Stakeholder Impact

• Shareholders: Received $1.75 cash per share and contingent value rights. Former DURECT shareholders no longer hold shares in an independent public company.
• Employees (specifically option holders): Those with in-the-money options likely benefited from acceleration and tender. Those with out-of-the-money options had them canceled but are eligible for retention bonuses tied to future performance.
• Company (DURECT): Now a wholly owned subsidiary of Bausch Health Americas, Inc., losing its independent public status.

Next Steps

• Achievement of specified milestones for contingent value right payments.
• Achievement of certain net sales milestones for cash retention bonuses for former option holders.

Key Dates

Keywords

DURECT Corporation, DRRX, Bausch Health Americas, Merger, Tender Offer, Contingent Value Right, CVR, Stock Options, Beneficial Ownership, SEC Form 4, Gail J. Maderis, Acquisition